SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Traders are closely monitoring the upcoming Federal Reserve meeting, with high expectations for a rate hike as sentiment remains bearish amid concerns over rising Treasury yields, inflation, and oil price volatility. While some participants weigh the potential impact of AI development slowdowns and ongoing geopolitical tensions on market stability, the conversation remains largely focused on the Fed's policy trajectory and its influence on broader market performance.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The community is debating the potential impacts of a Federal Reserve rate hike following reports of a 90% probability of an increase, while also reacting to conflicting signals regarding artificial intelligence development and rising Treasury yields.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending as traders debate whether the stock's recent price consolidation represents institutional accumulation or manipulation, with many investors maintaining a bullish long-term outlook based on fundamental growth and free cash flow despite the lack of immediate upward momentum. While some traders expressed frustration over the stock's failure to sustain rallies and its sensitivity to interest rate concerns and analyst downgrades, others highlight strong technical indicators and upcoming holiday season e-commerce tailwinds as catalysts for a potential reversal.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as traders focus on the upcoming HARMONi-3 clinical trial readout and a November FDA decision for ivonescimab, which is being positioned as a potential competitor to Keytruda. While sentiment remains divided over the drug's clinical data and the company's financial runway, the community is closely monitoring significant insider buying and elevated short interest as indicators of a possible short squeeze.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as traders react to rising long-term Treasury yields and shifting expectations for a potential Federal Reserve rate hike. The conversation remains divided, with some investors debating whether to buy the dip in bonds while others anticipate further downside due to ongoing inflationary pressures and energy market volatility.

ProShares Trust II - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

Traders are actively debating the structural decay of the instrument, with many expressing frustration over its failure to track volatility spikes during periods of market stress, frequently labeling it a "scam" due to consistent performance degradation. While some investors remain bearish on the broader market and hold positions for potential tail-risk events, others warn that its design as a short-term trading tool makes long-term holding highly unprofitable.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending as traders anticipate positive guidance updates and upcoming trial data, following recent healthcare conference appearances. Community sentiment remains bullish, with investors speculating on potential institutional accumulation and the company's long-term value driven by its TIL therapy platform.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco is trending as investors debate the impact of a newly announced partnership with Supermicro to integrate its rack-scale computing solutions into Cisco's Secure AI Factory platform. While some traders view the partnership as a significant long-term growth catalyst for AI infrastructure, others remain frustrated by the stock's recent stagnant price action and technical resistance at key levels.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is trending as investors weigh clinical data updates on its oncology pipeline against the company's recent leadership transition, with some traders expressing disappointment over the upcoming departure of the founders while others remain optimistic about the late-stage trial catalysts.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWM is experiencing volatility and downward pressure as traders weigh the impact of rising Treasury yields, higher oil prices, and uncertainty regarding Federal Reserve interest rate policy. The community is divided between those interpreting recent price action as a buying opportunity in a long-term uptrend and those concerned that the index is vulnerable to further downside, particularly given its technical weakness and sensitivity to macro headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Keen Vision Acquisition Corp. is a blank check company, which engages in effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, and reorganization or similar business combination. The company was founded on June 18, 2021 and is headquartered in Summit, NJ.

Keen Vision Acquisition Corp - Units (1 Ord & 1 War)

Neutral Sentiment

50bps hike

25bps hike

No change

25bps cut

The Federal Reserve's September FOMC meeting concludes Wednesday, September 16, with a rate decision due at 2:00 PM ET, following Tuesday's CPI report that showed inflation still running above the Fed's 2% target. What do you think the Fed decides at this week's FOMC meeting? Vote and explain your reasoning in the comments.

The Fed&#39;s rate decision comes Wednesday at 2PM ET. What do you think happens?

Stocktwits

The Fed's rate decision comes Wednesday at 2PM ET. What do you think happens?

Feed

News

Sentiment

Fundamentals

Info

KVACU News